about
Fibrates for primary prevention of cardiovascular disease eventsHub and switches: endocannabinoid signalling in midbrain dopamine neuronsUse of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative DatabasesFibrates for primary prevention of cardiovascular disease events.Fenofibrate and Diabetic Retinopathy.Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experienceFatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias.Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model.Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trialsImpact of the ENHANCE trial on the use of ezetimibe in the United States and CanadaImpact of drug policy on regional trends in ezetimibe useThe effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysisChemical and protein structural basis for biological crosstalk between PPARα and COX enzymes.Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.FDA Policy and Cardiovascular Medicine.Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence.Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.Lipids and diabetic retinopathy.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions.Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat.Identification and Characterization of Fenofibrate-Induced Liver Injury.National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey.PPAR-α, a lipid-sensing transcription factor, regulates blood-brain barrier efflux transporter expression.Intermolecular Amination of Unactivated C(sp3 )-H Bonds with Cyclic Alkylamines: Formation of C(sp3 )-N Bonds through Copper/Oxygen-Mediated C(sp3 )-H/N-H Activation.
P2860
Q24203618-DCB09141-9691-448A-94AA-10B315CC5DB2Q24623244-3741DCBF-02F1-4F14-B05A-B3169E622C68Q28548389-55AE6CA1-8647-4F90-B647-629B7A83EF8DQ30241199-AF98D2B0-2110-4823-A4DD-F57965B92F63Q30248492-0B5E277E-95EC-4AB2-9DEF-B69C793532A4Q30419020-A5871350-5DBB-4C63-A8B3-A15A9A0A1D8CQ33613330-B12471C4-6CDB-43FB-B3C0-A689ED1ECAA4Q33956562-F172EF0E-6188-433E-A6F5-CFB6E32DCB72Q34372885-24804C5D-1BA5-4257-A1D2-3D1C5313D964Q34428524-04F6AB66-670F-4277-B4E7-529631905167Q34432003-0DF04DB2-8350-4132-8090-C1622AB286EFQ34462245-DF00551E-466A-4E9B-879A-78CAB77A279FQ35210066-06D32A05-C41B-4AF7-8C6C-E18D3AE44084Q35453774-5BB866F1-746E-4DFA-A654-FC849854B0A0Q36035895-7D4E0D53-9DE0-4212-A1AB-B03CA2D9F94EQ36100416-A6CB3C1C-5529-4C90-9FEE-0AE34C1C2E76Q36796520-E73565C3-7722-452D-8FA9-1B9F5ACB08D3Q36939862-A076F78C-9CE4-46D5-8F84-F61FAAE78D0EQ37001217-A23F4708-8AFC-49DC-A34F-B9D696A90BD5Q37254899-6B9261D0-E25B-4242-BE0E-E22A50B2DC60Q37594791-23336A93-A8C1-496E-B25B-B2B5651EFC54Q37961883-43C77208-7998-4A72-94A3-7E67838EAE39Q38546242-59754C56-9A44-4309-AED2-B71554B2EA7EQ39090639-6E228A5F-E0CF-42A8-9C7A-CBA400D1EE0EQ39175937-C666079F-CBB8-4773-BBEC-AAD12BF96C49Q39414496-A09ED0B8-6F12-4601-921F-30D8EA4317E3Q42218338-E3C5EFE2-4277-4C9A-BB1C-BBF8F36CCF25Q42581553-BF8145B2-210A-42C8-877C-B6C7AB3ADD40Q47422605-64628823-AC32-45C1-B5BE-FACEB6288E96Q47649557-4F536A2E-A892-46D4-94C2-8594664952E2Q47710625-A136C272-0410-4CA3-B476-D689F0E20603Q54135102-E055AB07-A4D7-4E04-BEE1-BBC9F40C3B6E
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Use of fibrates in the United States and Canada
@ast
Use of fibrates in the United States and Canada
@en
type
label
Use of fibrates in the United States and Canada
@ast
Use of fibrates in the United States and Canada
@en
prefLabel
Use of fibrates in the United States and Canada
@ast
Use of fibrates in the United States and Canada
@en
P2860
P50
P356
P1476
Use of fibrates in the United States and Canada
@en
P2093
Cynthia A Jackevicius
Daniel Carreon
P2860
P304
P356
10.1001/JAMA.2011.353
P407
P577
2011-03-01T00:00:00Z